Sophie, your 13-year-old patient, visits your office for her quarterly checkup. All of her evaluations show that not much has changed since her last visit. Sophie’s FEV1 is 92% and she is in the 50th percentile for height and weight. Sophie’s mother comments that Sophie is coughing more than before, although neither Sophie nor her mother is concerned by the symptom. What, if anything, should you do for Sophie now?
Sophie: A Case Study in CF Management is an interactive and engaging program, led by Patrick Flume, MD and Michael Schechter, MD. As you respond to selections during the program, faculty-led discussions respond with tips and techniques to optimize treatment.
Patrick Flume, MD
Professor of Medicine and Pediatrics
The Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
Charleston, South Carolina
Michael S. Schechter, MD, MPH
Professor and Chief, Division of Pulmonary Medicine
Department of Pediatrics
Virginia Commonwealth University
Children's Hospital of Richmond at VCU
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Patrick Flume, MD: Consulting fees from Bayer Heathcare AG, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Horizon Pharma, Insmed, McKesson, Novartis, Proteostasis Therapeutics, Vertex Pharmaceuticals, Inc. Fees related to commercial interests: Bayer Heathcare AG, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Galapagos, Insmed, National Institutes of Health, Novartis, Novoteris, Proteostasis Therapeutics, Sound Pharmaceuticals, Inc., and Vertex Pharmaceuticals, Inc.
Michael S. Schechter, MD, MPH: Consulting fees from Vertex Pharmaceuticals, Inc. and commercial interest from Astra-Zeneca.
Launch Date: 10/23/18
Expiration Date: 01/31/20
To access activities, users will need: